Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

BACKGROUND: GSK3368715, a first-in-class, reversible inhibitor of type I protein methyltransferases (PRMTs) demonstrated anticancer activity in preclinical studies. This Phase 1 study (NCT03666988) evaluated safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of GSK3368715 in adults...

Descripción completa

Detalles Bibliográficos
Autores principales: El-Khoueiry, Anthony B., Clarke, James, Neff, Tobias, Crossman, Tim, Ratia, Nirav, Rathi, Chetan, Noto, Paul, Tarkar, Aarti, Garrido-Laguna, Ignacio, Calvo, Emiliano, Rodón, Jordi, Tran, Ben, O’Dwyer, Peter J., Cuker, Adam, Abdul Razak, Albiruni R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338470/
https://www.ncbi.nlm.nih.gov/pubmed/37237172
http://dx.doi.org/10.1038/s41416-023-02276-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10338470/
https://www.ncbi.nlm.nih.gov/pubmed/37237172
http://dx.doi.org/10.1038/s41416-023-02276-0

Ejemplares similares